AMRX Amneal Pharmaceuticals, Inc.
Company Analysis
Latest News
🟢 Amneal Pharmaceuticals is trading 4.37% up on November 9, 2026, amid broad U.S. market rebound
Amneal Pharmaceuticals is trading at $21.02, up +4.37%, alongside a broad U.S. market rebound. - Reuters described Monday’s recovery as bargain-hunting after...
🟢 Amneal Pharmaceuticals is trading 4.37% up today amid a broader market rebound
Amneal Pharmaceuticals is trading 4.37% up at $20.30 on November 6 amid a broader market rebound, alongside stronger-than-expected jobs data. - The gain...
🔴 Amneal Pharmaceuticals is trading 4.3% down in pre-market amid healthcare-sector weakness
Amneal Pharmaceuticals is trading at $18.62, down 4.3% in pre-market, with healthcare weakness a possible factor. - Shares closed at $19.45 on November 5,...
🔴 Amneal Pharmaceuticals is trading 6% down today; cause remains unclear
Amneal Pharmaceuticals is trading 5.89% lower at $19.02, with no confirmed catalyst for the decline. - November 3 results beat analyst expectations, and...
🔴 Amneal Pharmaceuticals is trading 4.21% down in pre-market after cutting cash-flow guidance
Amneal Pharmaceuticals is trading $19.36, -4.21% in pre-market on November 4, following its Q3 results and reduced cash-flow guidance. - It closed at $20.21...
Amneal Pharmaceuticals beats third quarter 2026 expectations and raises full year guidance
Amneal Pharmaceuticals reported third quarter 2026 results that exceeded analyst estimates on both top and bottom lines, driven by significant growth in its...
🔴 Amneal Pharmaceuticals is trading 4.14% down with no confirmed company-specific catalyst
Amneal Pharmaceuticals is trading at $20.62, down 4.14%, with no confirmed company-specific catalyst identified for the decline. - Amneal Pharmaceuticals is...
🔴 Amneal Pharmaceuticals is trading 4.23% down in pre-market with no confirmed company-specific catalyst
Amneal Pharmaceuticals is trading at $20.60, down 4.23% in pre-market; no confirmed company-specific catalyst for the decline was found. - Amneal...
Amneal Pharmaceuticals, Inc. Q3 2026 Earnings Preview: What Analysts Expect on November 03, 2026
Amneal Pharmaceuticals is projected to report Q3 2026 revenue of approximately $814.0 million and adjusted EPS of $0.23, while the stock currently trades at...
🟢 Amneal Pharmaceuticals is trading 4.02% up in pre-market amid healthcare's 1.32% pre-market gain
Amneal Pharmaceuticals is trading at $21.99, up 4.02%, with healthcare sector strength the clearest available context for its pre-market rise. - Healthcare...
🟢 Amneal Pharmaceuticals is trading 4.23% up on October 15, 2026, amid healthcare sector strength
Amneal Pharmaceuticals is trading at $19.70, up 4.23%, amid strength in healthcare shares. - Healthcare ETF XLV is up 2.12%, supported by strong earnings from...
🔴 Amneal Pharmaceuticals is trading 5.9% down in pre-market — no clear company-specific explanation
Amneal Pharmaceuticals is trading 5.9% lower pre-market at $18.50 on October 9, 2026, with no clear company-specific announcement explaining the decline. -...
🟢 Amneal Pharmaceuticals is trading 4.03% up with no clear catalyst identified
Amneal Pharmaceuticals is trading at $20.57, up 4.03% on September 28, with no verified catalyst identified for the intraday gain. - News coverage cited the...
🔴 Amneal Pharmaceuticals is trading 39.33% down in after-hours trading amid apparent profit-taking after FDA approval
Amneal Pharmaceuticals is trading at $11.83, down 39.33% in after-hours trading, in a move that appears consistent with profit-taking after the recent FDA...
🔴 Amneal Pharmaceuticals is trading 4.04% down today after profit-taking following lanreotide approval and launch
Amneal Pharmaceuticals is trading 4.04% down at $19.34, with the decline appearing to reflect profit-taking after FDA approval and immediate launch of generic...
Amneal Cracks Open a Nearly $1 Billion Drug Market — But Can It Hold Share in a Three-Way Fight?
Shares of Amneal Pharmaceuticals surged 10.85% to $20.74 after the FDA approved its generic version of a long-acting injectable used to treat rare hormonal...
🟢 Amneal Pharmaceuticals is trading 10.85% up today after FDA approval and immediate generic lanreotide launch
Amneal Pharmaceuticals is trading 10.85% up at $20.74 after FDA approval and immediate U.S. launch of generic lanreotide injection on September 18, 2026. •...
🟢 Amneal Pharmaceuticals is trading 5.77% up today after FDA approval and immediate generic lanreotide launch
Amneal Pharmaceuticals is trading 5.77% up at $19.79 after FDA approval and immediate U.S. launch of generic lanreotide injection. • FDA approval came...
Amneal wins FDA approval for generic cancer drug, eyes $983M market
Amneal Pharmaceuticals received FDA approval for its lanreotide injection, a generic equivalent to SOMATULINE Depot. The company plans an immediate commercial...
🟢 Amneal Pharmaceuticals is trading 4.2% up today as broader markets rise
Amneal Pharmaceuticals is trading at $18.84, up +4.20%, alongside broad risk-on sentiment. - The S&P 500 is up 0.91%, while the Nasdaq Composite is up...